ZYMFENTRA

Bio & Pharma Celltrion's Zymfentra gets 90% distribution channel in US

South Korean biosimilar maker Celltrion Inc. said on Monday its subcutaneous injection formulation for autoimmune diseases, Zymfentra (infliximab), ...

Bio & Pharma Celltrion's Zymfentra joins US insurance-covered drug lists

South Korean biosimilar maker Celltrion Inc. said on Monday that its subcutaneous injection formulation for autoimmune diseases, Zymfentra (inflixim...

Bio & Pharma Celltrion eyes M&A in Europe, $3.3 bn Zymfentra sales: chairman

WASHINGTON, D.C. – South Korean biosimilar giant Celltrion Inc. is accelerating its push to transform into a novel drug developer, going after...

Bio & Pharma Celltrion'a autoimmune disease drug Zymfentra makes US debut

South Korean biopharmaceutical giant Celltrion Inc. said on March 17 that it has launched its new autoimmune disease treatment Zymfentra in the US m...

Bio & Pharma Celltrion ships initial supply of Zymfentra to US

South Korea's Celltrion Inc. announced on Wednesday that it shipped the first supply of its subcutaneous injection type of the autoimmune disease tr...

Bio & Pharma Celltrion Healthcare's Remsima SC to be launched in US in 2024

Celltrion Healthcare Co. announced on Thursday that its autoimmune disease treatment Zymfentra (the US product name for Remsima SC) is set to be lau...